Payment overview · 2025
General Payments
$280.51
3 reported records · 3 companies
Healthcare provider profile · identity verified
Varun Bhatia, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EDISON, NJ · NPI 1255855995
Verified facts
What the public records show
CMS Open Payments records show Varun Bhatia, MD received $280.51 in general payments during 2025 across 3 reported records.
Abbott Laboratories accounted for 50.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 463 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $140.34 | 50.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $121.33 | 43.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.84 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $280.51 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $140.34 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $121.33 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
463 | 84 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 540 | 143 |
| Eliquis | Apixaban | 463 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 276 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 260 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 250 | 107 |
| Metoprolol Tartrate | Metoprolol Tartrate | 218 | 73 |
| Furosemide | Furosemide | 204 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 188 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 184 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 173 | 45 |
| Metformin Hcl | Metformin Hcl | 165 | 26 |
| Gabapentin | Gabapentin | 163 | 51 |
| Losartan Potassium | Losartan Potassium | 162 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 48 |
| Mirtazapine | Mirtazapine | 158 | 35 |
| Sertraline Hcl | Sertraline Hcl | 136 | 23 |
| Carvedilol | Carvedilol | 132 | 39 |
| Warfarin Sodium | Warfarin Sodium | 118 | suppressed |
| Omeprazole | Omeprazole | 116 | 32 |
| Divalproex Sodium | Divalproex Sodium | 113 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 43 |
| Montelukast Sodium | Montelukast Sodium | 103 | 18 |
| Midodrine Hcl | Midodrine Hcl | 98 | 54 |
| Potassium Chloride | Potassium Chloride | 98 | 38 |
| Lisinopril | Lisinopril | 95 | 34 |
| Trazodone Hcl | Trazodone Hcl | 91 | 17 |
| Levetiracetam | Levetiracetam | 71 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 19 |
| Famotidine | Famotidine | 70 | 28 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 67 | suppressed |
| Xarelto | Rivaroxaban | 66 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 12 |
| Prednisone | Prednisone | 64 | 48 |
| Tramadol Hcl | Tramadol Hcl | 60 | 20 |
| Simvastatin | Simvastatin | 58 | 13 |
| Clonidine Hcl | Clonidine Hcl | 55 | 22 |
| Bupropion Xl | Bupropion Hcl | 54 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 53 | 17 |
| Donepezil Hcl | Donepezil Hcl | 52 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 45 |
| Allopurinol | Allopurinol | 47 | 16 |
| Aripiprazole | Aripiprazole | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 25 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Clonazepam | Clonazepam | 43 | 13 |
| Lactulose | Lactulose | 43 | 15 |
| Entresto | Sacubitril/Valsartan | 42 | 12 |
| Torsemide | Torsemide | 42 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | 35 |
| Risperidone | Risperidone | 41 | suppressed |
| Procrit | Epoetin Alfa | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 12 |
| Finasteride | Finasteride | 35 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 33 |
| Nifedipine Er | Nifedipine | 34 | 21 |
| Divalproex Sodium Er | Divalproex Sodium | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Nystatin | Nystatin | 33 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 32 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | 15 |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 21 |
| Lorazepam | Lorazepam | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Olanzapine | Olanzapine | 28 | 17 |
| Spironolactone | Spironolactone | 28 | 17 |
| Baclofen | Baclofen | 27 | suppressed |
| Enulose | Lactulose | 27 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 20 |
| Albuterol Sulfate | Albuterol Sulfate | 26 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 26 | 24 |
| Naproxen | Naproxen | 26 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 25 | 12 |
| Digoxin | Digoxin | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Budesonide | Budesonide | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Repaglinide | Repaglinide | 23 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 23 | 11 |
| Latanoprost | Latanoprost | 22 | 13 |
| Azithromycin | Azithromycin | 21 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | 15 |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Metronidazole | Metronidazole | 20 | 16 |
| Pregabalin | Pregabalin | 20 | suppressed |
| Silodosin | Silodosin | 20 | suppressed |
| Alogliptin | Alogliptin Benzoate | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Methimazole | Methimazole | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Acetylcysteine | Acetylcysteine | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Abacavir | Abacavir Sulfate | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Lamivudine | Lamivudine | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $280.51 · 3 records | Abbott Laboratories | OPTIS, PAXLOVID, VOQUEZNA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error